Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder
Journal of Affective Disorders · 2025
DOI: 10.1016/j.jad.2025.01.064 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Affective Disorders, 2025. Verfasst von Sudeepa Bhattacharyya und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Sciences, Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR, USA. Hauptthemen laut MEDLINE: Cognitive Behavioral Therapy, Major Depressive Disorder, Duloxetine Hydrochloride, Escitalopram. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
]) were evaluated, both at baseline and after 12 weeks of treatment. Significant reductions in serum serotonin level and increases in tryptophan-derived indoles that are gut bacterially derived were observed with escitalopram and duloxetine arms but not in CBT arm. These include indole-3-propionic acid (I3PA), indole-3-lactic acid (I3LA) and Indoxyl sulfate (IS), a uremic toxin. Purine-related metabolites were decreased across all arms. Different metabolites correlated with improved symptoms in the different treatment arms revealing potentially different mechanisms between response to antidepressant medications and to CBT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Sciences, Arkansas Biosciences Institute, Arkansas State University, Jonesboro, AR, USA.
- Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA.
- Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, 221 Longwood Ave, LM322B, Boston, MA 02115, USA; Division of Sleep Medicine, Department of Medicine, Harvard Medical Schoo…
- Department of Psychiatry and Behavioral Sciences, Duke University, Durham, NC, USA; Duke-National University of Singapore, Singapore, Singapore.
- Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA.
- Department of Neurology and Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, USA.
Förderung
- National Institutes of Health
Zitieren
APA
Bhattacharyya, S., MahmoudianDehkordi, S., Sniatynski, M. J., Belenky, M., Marur, V. R., Rush, A. J., Craighead, W. E., Mayberg, H. S., Dunlop, B. W., Kristal, B. S., Kaddurah-Daouk, R., & Mood Disorder Precision Medicine Consortium (2025). Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder. Journal of Affective Disorders. https://doi.org/10.1016/j.jad.2025.01.064
Vancouver
Bhattacharyya S, MahmoudianDehkordi S, Sniatynski MJ, Belenky M, Marur VR, Rush AJ, et al. Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder. Journal of Affective Disorders. 2025. doi:10.1016/j.jad.2025.01.064
BibTeX
@article{Bhattacharyya2025,
author = {Bhattacharyya, Sudeepa and MahmoudianDehkordi, Siamak and Sniatynski, Matthew J and Belenky, Marina and Marur, Vasant R and Rush, A John and Craighead, W Edward and Mayberg, Helen S and Dunlop, Boadie W and Kristal, Bruce S and Kaddurah-Daouk, Rima and Mood Disorder Precision Medicine Consortium, Mood Disorder Precision Medicine Consortium},
title = {Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder},
journal = {Journal of Affective Disorders},
year = {2025},
doi = {10.1016/j.jad.2025.01.064}
}
EUVIMED